|
Originally published In Press as doi:10.1074/jbc.M105036200 on December 11, 2001
J. Biol. Chem., Vol. 277, Issue 9, 6903-6914, March 1, 2002
Intragenic Promoter Adaptation and Facilitated RNA Polymerase III
Recycling in the Transcription of SCR1, the 7SL RNA Gene of
Saccharomyces cerevisiae*
Giorgio
Dieci ,
Silvia
Giuliodori,
Manuela
Catellani,
Riccardo
Percudani, and
Simone
Ottonello§
From the Dipartimento di Biochimica e Biologia Molecolare,
Università di Parma, I-43100 Parma, Italy
Received for publication, June 1, 2001, and in revised form, December 7, 2001
 |
ABSTRACT |
The SCR1 gene, coding for the 7SL RNA
of the signal recognition particle, is the last known class III gene of
Saccharomyces cerevisiae that remains to be characterized
with respect to its mode of transcription and promoter organization. We
show here that SCR1 represents a unique case of a non-tRNA
class III gene in which intragenic promoter elements (the
TFIIIC-binding A- and B-blocks), corresponding to the D and T C arms
of mature tRNAs, have been adapted to a structurally different small
RNA without losing their transcriptional function. In fact, despite the
presence of an upstream canonical TATA box, SCR1
transcription strictly depends on the presence of functional, albeit
quite unusual, A- and B-blocks and requires all the basal
components of the RNA polymerase III transcription
apparatus, including TFIIIC. Accordingly, TFIIIC was found to protect
from DNase I digestion an 80-bp region comprising the A- and B-blocks.
B-block inactivation completely compromised TFIIIC binding and
transcription capacity in vitro and in vivo. An
inactivating mutation in the A-block selectively affected TFIIIC
binding to this promoter element but resulted in much more dramatic
impairment of in vivo than in vitro
transcription. Transcriptional competition and nucleosome disruption
experiments showed that this stronger in vivo defect is due
to a reduced ability of A-block-mutated SCR1 to compete
with other genes for TFIIIC binding and to counteract the assembly of
repressive chromatin structures through TFIIIC recruitment. A kinetic
analysis further revealed that facilitated RNA polymerase III
recycling, far from being restricted to typical small sized class III
templates, also takes place on the 522-bp-long SCR1 gene,
the longest known class III transcriptional unit.
 |
INTRODUCTION |
The most represented RNA polymerase III (Pol
III)1-transcribed genes,
those coding for the tRNAs and the 5 S rRNA, have a highly conserved
intragenic promoter comprising the binding sites for the general
transcription factor TFIIIC (A- and B-blocks) and for the 5 S-specific
factor TFIIIA (C-block). This conservation probably reflects the dual
function of the above elements as both nucleation sites for
transcription complex assembly and key determinants of tRNA and 5 S
rRNA structure. Within the same genes, in fact, an extremely high
sequence variability is displayed by the structurally unconstrained,
vicinal upstream region. This region provides the binding surface for
the initiation factor TFIIIB (1) and can modulate the strength of the
intragenic promoter (see Refs. 2-4 and references therein). TFIIIB,
which in yeast is minimally composed of the TATA-box-binding
protein, the TFIIB-related factor BRF (or TFIIIB70), and the Pol
III-specific factor B" (or TFIIIB90), is generally assembled on tRNA
genes in a TFIIIC-dependent manner (5). One extreme case of
5'-flanking sequence effect, however, has recently been documented for
some tRNA genes of Saccharomyces cerevisiae, which, due to
the presence of a canonical TATA box in their 5'-flanking region, are
capable of autonomous TFIIIB binding and TFIIIC-independent in
vitro transcription (6). Another indication of the constraints
imposed on intragenic promoter elements by their overlapping structural
and functional roles is the remarkable variability of promoter
organization displayed by the minority of class III genes not coding
for tRNAs and 5 S rRNAs. One group of such genes, well exemplified by
the metazoan U6 snRNA and the human 7SK RNA genes, entirely relies for
transcription on upstream promoter elements similar to those of RNA
polymerase II-transcribed genes. Another group, which includes the
Xenopus selenocysteine tRNA gene and the
EBER2 gene of the Epstein-Barr virus, is
characterized by mixed promoters composed of both intragenic and
extragenic elements (reviewed in Ref. 5). The highly flexible organization of these genes is best illustrated by the 7SL RNA genes,
coding for the conserved RNA component of the signal recognition particle, which in eukaryotes have undergone a remarkable variation in
their mode of transcription. In humans, 7SL RNA gene transcription requires both an extended upstream region (7), including a binding site
for the RNA polymerase II activator ATF (8), and an unusual intragenic
promoter element that stimulates transcription through a structural
motif at the 5' end of the nascent transcript (9-11). At variance with
the human genes, plant 7SL gene transcription only requires an upstream
promoter composed of a TATA box and an upstream stimulatory element
identical to that of all plant U-snRNA gene promoters (12). Yet another
promoter organization is found in the 7SL genes of protozoans of the
family Trypanosomatidae, whose transcription depends on the A- and
B-blocks of a divergently oriented, companion tRNA gene positioned 100 bp upstream of the 7SL transcription start site (13, 14). As a final
example of promoter divergence, the 7SL genes of the yeasts
Schizosaccharomyces pombe and S. cerevisiae both
contain intragenic sequences resembling the A- and B-blocks (15, 16),
but an upstream TATA box has been shown to play an essential
transcriptional role in the fission yeast 7SL RNA gene (17). Despite
the critical evolutionary position of S. cerevisiae as one
of the most primitive lower eukaryotes and the fact that its RNA
polymerase III transcription system is by far the best characterized
biochemically, the 7SL RNA gene of this organism, SCR1, is
still uncharacterized. This single copy gene was identified more than a
decade ago because of the extremely high abundance of its RNA product
(15) but was never subjected to transcriptional analysis, and only very
recently was it shown to be transcribed by RNA polymerase III (18). In particular, the contribution of the putative A- and B-blocks and the
factor requirement for SCR1 transcription are unknown.
Another interesting, as yet unanswered question is how the very
abundant SCR1 product, which accounts for ~0.2% of total
yeast RNA (15), can be efficiently synthesized from a single copy gene.
By taking advantage of a highly purified and well characterized RNA
polymerase III in vitro transcription system and of a viable, slow growth S. cerevisiae strain lacking
SCR1 (19), we have carried out an extensive in
vitro and in vivo analysis of SCR1 promoter
architecture, initiation complex assembly, and transcription elongation
and reinitiation properties.
 |
MATERIALS AND METHODS |
Sequence Analysis of SCR1--
198 types of A-block sequences
and 60 types of B-block sequences were derived from the alignment of
931 eukaryotic tRNA gene sequences.2 These unique
sequences were used to construct updated weight matrices for Pol3scan
(available on the World Wide Web at
irisbioc.bio.unipr.it/pol3scan.html), a program based on weight matrix
analysis of tRNA gene promoters (20). Pol3scan, with properly modified
cut-off parameters, was then used to locate A- and B-block-like
elements in SCR1.
Amplification and Cloning of SCR1--
The S. cerevisiae SCR1 gene was PCR-amplified from yeast genomic DNA
(strain S288C) using the high fidelity Deep Vent DNA polymerase (New
England Biolabs) and the following oligonucleotide primers: SCR1fw
(5'-TGATCAACTTAGCCAGGACATCC) and SCR1rev (5'-GTTCTAAGTATTCTCATTTTATCC). Amplification conditions and insertion into the pBlueScript KS (+)
vector (Stratagene) were as described (6). The identity of the 992-bp
amplified fragment, containing the SCR1 coding sequence (522 bp) plus 246 bp of 5'-flanking and 224 bp of 3'-flanking sequences, was
verified by dideoxy chain termination sequencing. The sequence of the
amplified SCR1 fragment, which exactly matches the one
retrieved from the Munich Information Center for Protein Sequences
(MIPS) Web site (mips.gsf.de/proj/yeast/CYGD), presents some
differences in the coding region with respect to the originally published SCR1 sequence (15). These are three insertions (G at position +49, G at position +98, and C and A at positions +362 and
+363, respectively) and one deletion (a missing G between positions
+403 and +404); numbering refers to the MIPS (and our) sequence of the
SCR1 coding region.
In Vitro Mutagenesis of Putative SCR1 Promoter
Elements--
The 5' -32, TATAdown, Adown, and C4T SCR1
mutants were obtained by PCR using wild type SCR1 in
pBlueScript-KS (pBlueScript-SCR1) as template and the
SCR1rev oligonucleotide (see above) together with the following
mutagenic 5' oligonucleotides (mutated positions are underlined)
as primers: 5' -32, 5'-GTATAAAATCGAAAGTTTATTCCAATTG; TATAdown,
5'-GTGTAAAATCGAAAGTTTATTCCAATTG; Adown,
5'-GTATAAAATCGAAAGTTTATTCCAATTGTGCTAGGCTGTAATGGCTTTCTCCTGGGATGGGATACG; C4T, 5'-GTATAAAATCGAAAGTTTATTCCAATTGTGCTAGGTTGTAATGG.
The (A/TATA)down mutant was derived from SCR1 Adown
by mutagenic PCR using TATAdown and SCR1rev primers. The Bdown
SCR1 mutant was constructed by recombinant PCR (21). Two
overlapping PCR primary products were generated using the 5' -32
oligonucleotide in combination with Bdown-rev
(5'-CGCGAGGAAGGATTTCTTCCTGGCC) and the SCR1rev
oligonucleotide in combination with the Bdown-fw primer (5'-GGCCAGGAAGAAATCCTTCCTCGCG). Mutated positions in
Bdown-rev and Bdown-fw are underlined. After gel purification,
primary amplification products were mixed and used as templates in
a subsequent amplification reaction, employing SCR1fw and SCR1rev as
"outside" primers, which yielded the desired full-length secondary
product. The 3' +90 mutant was obtained by PCR using WT
SCR1 as template, the 5' -32 oligonucleotide as a forward
primer, and the 3' +90 oligonucleotide (5'-AAAAAAACGTGCAATCCGTGTCTAGCCGCG) as a reverse primer, which allowed
us to introduce an artificial Pol III terminator. All of the mutated
SCR1 fragments were inserted into the pGEM-T Easy vector
(Promega) and sequence-verified. For in vivo analyses, SCR1 variants were subcloned as
BamHI-HindIII (WT SCR1) or
SphI-SacI (all of the mutants) fragments into the
YEp352 vector (22) cut with the same enzymes. All restriction and
modification enzymes were from Amersham Biosciences, Inc.
In Vitro Transcription Assays--
Multiple round and single
round in vitro transcription of SCR1 using
recombinant or purified Pol III transcription components was carried
out as described (6) except for the use of SUPERase-In (Ambion) as an
RNase inhibitor. In the single round transcription experiments of Fig.
7, B and C, UTP was present at a concentration of
100 µM. The heparin resistance of the 12-mer
RNA-containing ternary complex assembled on SCR1-C4T (Fig.
7A) was evaluated as follows. Ternary complexes were
assembled by incubating SCR1-C4T template and transcription
components in the presence of 0.5 mM ATP and GTP and 2.5 µM [ -32P]UTP (Amersham Biosciences; 800 Ci/mmol). The output of a single round of transcription was then
evaluated by adding CTP (0.5 mM), together with excess
unlabeled UTP (2 mM), with or without 100 µM
heparin, and allowing transcript elongation to proceed for 1 min. RNA
size markers were generated by T7 RNA polymerase (Amersham Biosciences)
in vitro transcription (23) of linearized pBlueScript-KS constructs bearing inserts of different sizes in the SmaI
site: the S. cerevisiae I(TAT)LR1 tRNA gene and flanking
regions (302 bp (6)) and the sequences coding for yeast ribosomal
proteins L13 (600 bp (23)) and S24 (408 bp).3
DNase I Footprinting and Gel Retardation Assays--
For the
DNase I footprinting experiment in Fig. 4A, a 992-bp
SCR1 fragment, 5'-end-labeled on the sense strand, was
generated by PCR using 5'-labeled SCR1fw and unlabeled SCR1rev as
primers and pBlueScript-SCR1 as a template. The fragments
utilized for the footprinting experiments of Fig. 4B (256 bp) were 5'-end-labeled on the antisense strand by PCR using a
5'-labeled oligonucleotide primer hybridizing between positions +224
and +200 (5'-GCCGGGACACTTCAGAACGGAC), the 5' -32 oligonucleotide
as a forward primer, and the SCR1 5' -32, Adown, and Bdown
mutants as PCR templates. Radiolabeled fragments were purified by
agarose gel electrophoresis followed by elution with the QIAquick Gel
Extraction Kit (Qiagen); the specific radioactivity of purified
fragments (250 ng each) was about 1500 cpm/fmol. DNase I digestion
mixtures (20 µl) contained 16 fmol of the SCR1 fragment, 10 ng/µl pBlueScript-KS, 20 mM Hepes/KOH (pH 8.0), 170 mM KCl, 5% (v/v) glycerol, 0.1 mg/ml ultrapure bovine
serum albumin (Ambion), 0.5 mM dithiothreitol, and 50-100
ng of affinity-purified TFIIIC (24). Briefly, TFIIIC-DNA complexes,
formed upon incubation for 15 min at 20 °C, were treated for exactly
1 min with 0.35 ng of pancreatic deoxyribonuclease I (Amersham
Biosciences; E2215Y type), followed by the addition of 22 µl of
blocking solution (20 mM EDTA, 1% (w/v) SDS, 0.2 M NaCl). Footprinting mixtures were phenol-extracted,
ethanol-precipitated in the presence of 30 µg of carrier RNA (Sigma;
R 6625 type), and fractionated on 6% polyacrylamide, 7 M urea sequencing gels, which were then dried and
phosphorimaged with a Personal Imager FX (Bio-Rad). DNA fragments for
gel retardation assays were radiolabeled by PCR, using 5'-labeled amplification primers as described above for the preparation of DNA
fragments for footprinting analysis. DNA binding reactions were
conducted in a final volume of 15 µl and contained 25 mM Tris-HCl (pH 8.0), 10% glycerol, 90 mM
(NH4)2SO4, 1 mg/ml ultrapure bovine
serum albumin, 15 µg/ml supercoiled plasmid DNA (pBlueScript-KS), 4 fmol of radiolabeled DNA fragment (~8,000 cpm), and varying amounts
of TFIIIC purified up to the DEAE-Sephadex A-25 step (24). Native gel
electrophoresis and subsequent analysis were carried out as described
(25).
In Vivo RNA Analyses--
The yeast strain YRA130 (a kind gift
of Peter Walter, University of California, San Francisco), in which the
entire SCR1 gene, except for the first 14 nucleotides, has
been deleted and replaced with the HIS3 gene (19), was
utilized for in vivo complementation and expression assays.
This strain was transformed with the different YEp352-SCR1
constructs by the lithium acetate procedure (26), and the resulting
transformants were selected for uracil auxotrophy on SD plates
supplemented with tryptophan, lysine, and adenine. Total RNA was
prepared according to a previously described procedure (27). Primer
extension reactions were carried out as described (6), using 5 µg of
total yeast RNA and a 5'-labeled oligonucleotide primer
(5'-CCCTTGCCAAAGGGCGTGCAATCCG) complementary to the coding region of
SCR1 between positions +90 and +115. Complementation of the
YRA130 slow growth phenotype (19) was qualitatively evaluated by visual
inspection of selective (SD) or nonselective (YPD) plates, on which
cultures of freshly transformed clones were spotted.
Strains UKY403 and MHY308 (a kind gift of Michael Grunstein (UCLA))
were employed to analyze the effects of nucleosome disruption on
SCR1 transcription. Strain UKY403, in which the two histone H4 genes have been disrupted, survives with a unique, centromeric plasmid-borne histone H4 gene under the control of the GAL1
promoter (28). MHY308 is isogenic to UKY403, except that its sole
histone H4 gene is under the control of its own wild type promoter
(29). Both strains were transformed with YEp352 constructs carrying WT
and mutant (5' -32 and Adown) SCR1 minigene variants, in
which 120 bp at the 3' terminus had been deleted by PCR using the
SCR1_mini oligonucleotide (5'-AAAAAAAATGTGCTATCCCGGCCGCCTCC) as a
reverse primer, either SCR1fw or 5' -32 as forward primers, and WT or Adown SCR1 as PCR templates. The SCR1_mini oligonucleotide
introduces an artificial terminator sequence at position +400 of the
SCR1 sequence, so that transcription of the various minigene
templates yields ~400-nt-long transcripts that are easily
distinguishable from the endogenous 522-nt-long SCR1 RNA.
The glucose shift experiment was carried out as described previously
(30). For RNA gel blot analysis, RNA samples (5 µg) were
electrophoresed on 6% polyacrylamide, 7 M urea gels and
transferred to Hybond-N membranes (Amersham Biosciences), which were
then probed with the same 5'-labeled oligonucleotide utilized for
primer extension analysis. Hybridization was carried out overnight at
28 °C in 5× SSC, 5× Denhardt's solution, 0.1 mg/ml denatured
salmon sperm DNA, 0.5% (w/v) SDS, followed by three short washings in
2× SSC, 0.1% SDS. Hybridization products were visualized by
autoradiography and quantified by phosphorimaging.
 |
RESULTS |
Predicted Control Elements of the SCR1 Gene--
Pol3scan, a
program based on weight matrix analysis of tRNA gene promoters (20,
31), was used to locate A- and B-blocks in the SCR1
sequence. No such element was identified with the default cutoff score
( 34.14) usually employed for the identification of tRNA gene
promoters. With a more permissive cutoff ( 38), however, putative A-
and B-blocks, with a spacing almost perfectly matching that of mature
tRNAs, were identified at positions +9 and +51, respectively (Fig.
1A). A search of the Signal
Recognition Particle Database (32), conducted with the same parameters,
revealed the presence of A- and B-blocks above the 38 cutoff
threshold only in the case of fungal 7SL RNA genes (Yarrowia
lipolytica and S. pombe). In tRNA genes, these two
promoter elements code for highly conserved structural modules of the
tRNA (the D and T C arms, respectively); their sequence conservation
is thus influenced by factors not necessarily related to promoter
strength. As shown in Fig. 1B, the A- and B-blocks of
SCR1 are embedded in a very distinct structural context, so
that sequence variations may be expected because of the different
structural constraints. Indeed, the putative promoter elements of
SCR1 display distinguishing features as compared with the
consensus of the tDNA A- and B-blocks (Fig. 1A). The most
prominent of them is the substitution of the canonical B-block starting
sequence GGTT (in which the invariant T at the fourth position
corresponds to the precursor of the essential pseudouridine residue of
the tRNA T C arm) with GGAA, a sequence that never occurs in tRNA
gene promoters but is present in RPR1, another noncanonical
yeast class III gene coding for the RNA subunit of RNase P (33).
Another sequence feature never occurring in tRNA genes, but found in
SCR1, is TC at positions +16 and +17, corresponding to
positions +14 and +15 of the consensus tRNA gene A-block (Fig.
1A; numbering starts from the first position of the mature
tRNA), which are sites of important tertiary interactions in tRNA
structure (34). Other, more evident features of SCR1 are a
TATA element upstream of the transcription start site (position 31)
and, as already noted (15), a typical T-rich terminator element at
position +518.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
SCR1 control elements identified by weight
matrix analysis. A, frequency matrices for tRNA gene
promoter regions. Each column corresponds to an individual
position along the A-block or B-block sequence. Intragenic promoter
boundaries for a consensus tRNA are +7/+25 (A-block) and +52/+62
(B-block) and are referred to a mature tRNA sequence. The
top line (Total) indicates the total
number of unique tRNA sequences in which each position is represented.
Columns where this number is lower than the sample number
(198 for the A-block and 60 for the B-block) indicate a position that
in some cases is deleted. The SCR1 putative promoter
elements identified with Pol3scan (score = 37.95) are compared
with the 75% consensus of the frequency matrix. The consensus is
written following IUPAC notations: R = G/A; Y = T/C; B = G/C/T; V = G/C/A; D = G/A/T; N = G/C/A/T. B,
secondary structure model of the 5'-end of the S. cerevisiae
7SL RNA (adapted from Ref. 46). The sequences corresponding to the A-
and B-blocks are shown in boldface type. Mutations in the putative
promoter elements analyzed in this study are indicated in
boxes above the wild type sequence.
|
|
In Vitro Transcription of SCR1--
The coding region of
SCR1, plus 246 bp of 5'-flanking and 224 bp of 3'-flanking
sequence, was PCR-amplified from S. cerevisiae genomic DNA
and inserted into the pBlueScript KS vector. The resulting construct
was then assayed in a Pol III-specific in vitro
transcription system containing balanced amounts of recombinant
TATA-box-binding protein and BRF proteins, partially purified B" and
TFIIIC fractions, and highly purified RNA polymerase III (6, 24).
Transcription products were run on a polyacrylamide/urea gel (Fig.
2A, lane 4) in
parallel with standard RNAs of known size produced by T7 RNA polymerase
(Fig. 2A, lanes 1-3). A single transcript, with a size very close to that of the natural scR1 RNA (519 nt for strain
ATCC 25657 (15) and 522 nt for strain S288C; see "Materials and
Methods"), was synthesized in the in vitro reconstituted
Pol III system. A comparison between the in vitro and the
in vivo synthesized scR1 RNA is presented in Fig.
2B, which shows the results of a primer extension analysis
that was carried out to map the SCR1 transcription start
site. Both in vitro (lane 1) and
in vivo (lane 2) synthesized
transcripts initiated at the same A residue corresponding to the first
nucleotide of the scR1 RNA (15). Thus, the in vitro
reconstituted Pol III system supports the efficient and faithful
transcription of the SCR1 gene. The transcription factor
requirements for scR1 RNA synthesis are reported in Fig. 2C,
which shows that both TFIIIC and the three components of yeast TFIIIB
are essential for SCR1 transcription. Very low levels of
TFIIIC-independent transcription were observed in some experiments. In
accord with the presence of a TATA element at position 31 (6), this
background, TFIIIC-independent transcription was abolished by TATA-box
inactivation (data not shown). When the natural B" fraction was
replaced by recombinant yeast TFIIIB90 (35), SCR1
transcription was reduced by about 7-fold and was not significantly
stimulated by the addition of the TFIIIE fraction (data not shown
(36)).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
SCR1 RNA synthesis in a reconstituted
in vitro transcription system. A, the
size of in vitro synthesized SCR1 (lane
4) was measured by comparison with marker RNAs of the indicated
sizes in nucleotides (lanes 1-3, M). The
arrowhead on the right indicates the migration
position of the SCR1 transcript. B, the RNA
products of a 2 times scaled up in vitro transcription
reaction programmed with the SCR1 template (lane
1, in vitro), or 5 µg of in vivo
synthesized total RNA (lane 2, in vivo) were
subjected to primer extension analysis as described under "Materials
and Methods." The migration position of the fully extended
SCR1-specific primer is indicated on the left
(scRNA). Shown in lanes 3-6 are the results of
dideoxy chain termination sequencing reactions conducted with the same
5'-labeled oligonucleotide utilized for primer extension. The sequence
of the nontranscribed DNA strand around the start site (+1)
is indicated on the right. C, SCR1 in
vitro transcription was carried out either in the presence of the
entire set of Pol III components (lane 1,
ALL) or in partially reconstituted systems lacking the
individual transcription components indicated above each
lane.
|
|
Organization of the SCR1 Promoter--
Mutations were next
introduced into the different putative control elements previously
identified by sequence analysis, and the resulting mutants were assayed
for template activity both in vitro and in vivo.
For the in vivo analysis, mutagenized SCR1 derivatives were inserted into the multicopy plasmid YEp352 (22) and
transformed into the scr1::HIS null mutant strain YRA130
(19). This strain displays a slow growth phenotype that could be
reversed upon introduction of the wild type SCR1 gene
carried by YEp352 (not shown). This enabled us to monitor the
phenotypic effects of the introduced mutations. Fig.
3A summarizes the
transcription activities and functional complementation phenotypes of
the different mutants, whereas Fig. 3, B and C,
shows representative results of in vitro (Fig.
3B) and in vivo (Fig. 3C)
transcription analysis. In the experiment of Fig. 3C, the
steady state levels of the 7SL RNA were measured by primer extension in
the transformed null mutant. This allowed us to reveal simultaneously
the in vivo transcriptional output of SCR1
mutants as well as possible defects in start site selection. The
results of these experiments showed that the B-block is the only
cis-acting element absolutely required for SCR1
transcription. In fact, a C56G point mutation within such an element
abolished transcription in vitro (Fig. 3B,
lane 4), reduced the in vivo steady state amount
of the 7SL RNA to undetectable levels (Fig. 3C, lane
4), and completely destroyed complementation capacity (Fig.
3A). By comparison, a double point mutation in the A-block (CC in place of GG at the universally conserved +19 and +20 positions; Adown mutant) had a much less severe effect on in vitro
transcription (Fig. 3B, compare lane 5 with
lane 2), even in combination with a TATA box-inactivating
mutation (lane 6). The same A-block mutation, however,
reduced in vivo 7SL RNA levels by about 20-fold as compared with wild type SCR1 (Fig. 3C, lanes 5 and 6) and resulted in a partial loss of slow growth
complementation (Fig. 3A). In tRNAs, the A-block region is
an important structural determinant, and reduced in vivo
levels of SCR1 Adown transcripts might thus in principle
derive from a decreased stability of the RNA product, rather than from
a transcription defect. This possibility was tested by RNase A
digestion experiments, which revealed an identical nuclease sensitivity
(with respect to enzyme amount and time course of degradation) of
in vitro synthesized, wild type and Adown
SCR1 transcripts (data not shown). A less dramatic in
vitro/in vivo discrepancy was observed with a mutant (5' -32)
carrying a deletion of the SCR1 5'-flanking region from 245 to 33.
This mutation resulted in a slightly increased transcription efficiency
in vitro (Fig. 3B, lane 2), while it
caused a 4-fold decrease of in vivo SCR1 transcription (Fig.
3C, lane 2), a relatively small effect that was
not reproduced in independent experiments carried out in a different
yeast strain with a 3'-truncated version of the 5' -32 mutant (see
below). Similarly, inactivation of the TATA box in the 5' -32 context
did not produce any significant effect (Fig. 3, B and
C, lanes 3), and also without effect on in
vitro transcription was the deletion of the entire SCR1
coding sequence downstream of the B-block (Fig. 3B,
lane 7). In the latter case, the introduction of an
artificial T (7) terminator at position +90 led to the synthesis of a
correspondingly shortened (~90-nt-long) transcript. The apparently
reduced accumulation of this transcript is not due to a transcriptional
defect but simply reflects the decreased incorporation of radiolabeled
U residues during in vitro transcription. In fact,
normalization for the number of incorporated U residues gave an
estimate of in vitro transcription efficiency identical to
that of the WT SCR1 gene (Fig. 3A). Also, at
variance with the yeast U6 snRNA gene, in which TATA box and A-block
mutations have been shown to result in an altered initiation site
selection (37-39), transcription correctly initiated at the same A
residue, both in vivo and in vitro, in all of the
tested SCR1 mutants (Fig. 3C, lanes 3,
5, and 6; data not shown).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Transcriptional and complementation
phenotypes of SCR1 mutants. A,
schematic representation of the different SCR1 mutants.
Putative intragenic (filled boxes) or extragenic
(empty boxes) control elements and the transcription
termination site (Tn) are indicated; crossed
boxes indicate mutagenized elements (see "Materials
and Methods" for details). In vitro transcription levels,
reported in the first column, are given as
percentages of wild type SCR1 transcription; values are
the average of at least five independent measurements that differed by
no more than 15% of the mean. Normalized transcription values for the
3' +90 mutant (asterisk; see also lane 7 in
B) were calculated by taking into account that 5 times fewer
U residues are incorporated into the early truncated 3' +90
transcript as compared with WT scR1. In vivo expression
levels, reported in the middle column,
were determined by primer extension analysis of total RNA extracted
from the YRA130 strain transformed with plasmids carrying the different SCR1 variants. The
reported values, expressed as percentages of the RNA levels obtained
with WT SCR1, were normalized using the
tRNAIle(UAU) as an internal standard (see C).
Complementation of the slow growth phenotype of the YRA130 strain by
the different mutants and by WT SCR1 is reported in the
third column. , no complementation; +,
intermediate complementation; ++, full complementation; ND,
not determined. B, in vitro transcription of wild
type (lane 1) and mutant (lanes 2-7)
SCR1 genes. The migration positions of full-length
(scRNA) and 3'-truncated ( +90) SCR1
transcripts are indicated on the right. C,
in vivo transcriptional output of wild type (lane
1) or mutant (lanes 2-6) SCR1 genes
determined by primer extension. The migration position of the fully
extended SCR1-specific product is indicated on the
left (scRNA). Shown on the right are
the results of dideoxy chain termination sequencing reactions primed
with the same radiolabeled oligonucleotide utilized for primer
extension (lanes G, T, A, and
C). The sequence of the nontranscribed strand around the
start site (+1) is indicated on the right.
tRNAIle(UAU) extension products, obtained from the same RNA
samples and utilized as internal controls, are shown at the
bottom.
|
|
Binding of TFIIIC to the SCR1 Gene--
As revealed by the above
results, the A- and B-blocks located within the first 70 bp of the
SCR1 coding region are essential promoter elements. To
verify whether such elements behave like the internal promoters of tRNA
genes, binding of TFIIIC to SCR1 was analyzed by DNase I
footprinting. As shown in Fig.
4A, TFIIIC protected the
entire intragenic region from position +5 to +84 of the sense strand (5 bp upstream of the A-block to 23 bp downstream of the B-block). Both
the extent of the observed protection and the presence of an
intensified cleavage site at the 3' border of the protected region
closely resemble the protection patterns previously reported for yeast
tRNA genes (40) and the tRNA-like leader of the RPR1 gene
(33). The TFIIIC-binding properties of the Adown and Bdown
SCR1 templates were then examined to find out whether the
TFIIIC binding ability of such mutants correlates with their in
vitro and/or in vivo transcription activity. As shown
in Fig. 4B, on the 5' -32 template, bearing wild type A- and B-blocks and utilized as a control for these experiments
(lanes 5-7), TFIIIC protected a region comprised between
positions +9 (the 5' border of the A-block, also corresponding to a
site of intensified cleavage), and +77 (16 bp downstream of the
B-block) of the antisense strand. In contrast, TFIIIC binding was
completely abolished in the case of the Bdown template (lanes
11-13), in which the C56G mutation per
se determined a local alteration of the DNase I sensitivity
pattern (compare lane 11 with lanes 5 and
8). A somewhat intermediate situation was observed in the case of the Adown template (lanes 8-10). Here, the
interaction of TFIIIC with the B-block was barely affected, whereas
protection was significantly decreased from position +9 (with the loss
of the TFIIIC-induced hypersensitive site) to +38 (12 bp
downstream of the A-block). Thus, the A-block mutation interferes with
the correct positioning of the upstream portion of TFIIIC. As further revealed by the gel retardation experiment reported in Fig.
5A, an immediate consequence
of this suboptimal promoter occupancy is a reduced affinity for TFIIIC.
In fact, the Adown template was much less effective than the control
5' -32 template in TFIIIC binding (compare lanes 4-7 with
lanes 11-14), and a 9-fold reduction in TFIIIC-Adown
SCR1 DNA complex formation, as compared with WT SCR1 (compare lanes 4 and 11), was
observed in the presence of 100 ng of partially purified TFIIIC, the
standard amount used for in vitro transcription
experiments.

View larger version (76K):
[in this window]
[in a new window]
|
Fig. 4.
Binding of TFIIIC to
SCR1. A, TFIIIC binding to WT
SCR1. A WT SCR1-containing fragment (16 fmol),
radiolabeled on the sense strand, was incubated in the presence
(lane 2) or in the absence (lanes 1 and
3) of affinity-purified TFIIIC (75 ng), digested with DNase
I, and processed as described under "Materials and Methods." Shown
in lanes 4-7 are the results of dideoxy chain termination
sequencing reactions conducted with the same radiolabeled
oligonucleotide utilized to amplify the SCR1 fragment.
Sequence element references on the coding (thick solid bar,
+1 and above) and the upstream nontranscribed (thin solid
bar, 100 to +1) regions of SCR1 are indicated on the
left. B, TFIIIC binding to SCR1
mutants. DNA fragments radiolabeled on the antisense strand and
containing the 5' -32 (lanes 5-7), Adown (lanes
8-10), or Bdown (lanes 11-13) SCR1
derivatives were incubated with the indicated amounts of TFIIIC before
DNase I digestion. Reference sequencing reactions were run in
lanes 1-4. Indicated on the right are the
positions of the A- and B-blocks and the borders (+9/+77) of TFIIIC
protection.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 5.
TFIIIC binding and competition ability of
A-block-mutated SCR1. A, the indicated
amounts of TFIIIC were incubated with radiolabeled fragments (4 fmol)
derived from either 5' -32 (lanes 1-7) or Adown
(lanes 8-14) SCR1 derivatives, followed by
electrophoretic fractionation of TFIIIC-bound and free DNA molecules on
a native polyacrylamide gel. B, in vitro
transcription reactions were conducted in reaction mixtures containing
20 fmol of either WT (lanes 1-7) or Adown
(lanes 8-14) SCR1 and increasing
concentrations of a tDNAPro(TGG) competitor (6) at the
molar ratios indicated above each lane. The
migration positions of SCR1 (scRNA) and
tDNAPro (Pre-tRNAPro) transcripts
are indicated on the right.
|
|
The decreased in vivo RNA output of the Adown
mutant thus appears to correlate with a defective TFIIIC binding, while
the in vitro/in vivo transcription discrepancy
observed with the same mutant (Fig. 3) may be explained by the lack, in
the purified in vitro system, of both competitor templates
and interfering chromatin structure effects. This hypothesis was first
tested by transcription competition experiments, reported in Fig.
5B, in which wild type SCR1 (lanes
1-7) or the Adown mutant (lanes 8-14) were
transcribed in vitro in the presence of increasing concentrations of a competitor tRNAPro gene. Transcription
of the Adown mutant was much more sensitive to tDNAPro
competition than WT SCR1 transcription. For example, in the
presence of an equimolar amount of competitor DNA, WT SCR1
transcription was reduced by 2-fold (compare lanes 1 and
4) as compared with the 20-fold inhibition observed under
the same conditions with the Adown mutant (compare lanes 8 and 11), a 10-fold effect approaching the previously
measured difference between in vitro (uncompeted) and
in vivo transcription (Fig. 3). This marked competition
sensitivity specifically pertains to the Adown mutant, because no such
effect was observed in similar competition experiments conducted with the upstream SCR1 deletion mutant 5' -32 (data not shown).
We then asked whether chromatin-mediated transcriptional interference
could also contribute to the much more dramatic defect displayed by the
Adown SCR1 mutant under in vivo conditions. A yeast strain (UKY403) in which the two genes coding for histone H4 have
been disrupted and which survives with a single histone H4 gene under
the control of the GAL1 promoter was used to test this
hypothesis (28). Shifting the UKY403 strain to a glucose-supplemented medium blocks histone H4 gene expression, thus causing a global disruption of chromatin structure and consequent growth arrest. For the
experiment of Fig. 6, this strain and the
control strain MHY308 (isogenic to UKY403 except that its sole histone
H4 gene is under the control of its own WT promoter and is thus
glucose-insensitive (29)) were transformed with WT or Adown
SCR1 constructs carrying 3'-shortened derivatives of both
genes, so as to distinguish between plasmid-derived and endogenous,
full-length SCR1 transcripts. Transformants were grown to an
A600 value of 0.5 in selective galactose medium
and then shifted to glucose-containing medium for an additional 6 h, and total RNA from both cultures was subjected to RNA gel blot
analysis. The levels of shortened RNAs transcribed from episomal
SCR1 minigenes were in general much lower than those of
endogenous SCR1 transcripts, most likely because of a
decreased in vivo stability of the truncated RNAs. In either
strain, Adown SCR1 transcripts were undetectable during
growth on galactose (lanes 2 and 6) and were
still undetectable in the control strain after a shift to the glucose
medium (lane 4). Interestingly, however, Adown transcript
levels rose to up to 40% of those of WT SCR1 upon glucose
shift of the UKY403 strain (compare lanes 7 and
8), in which chromatin had been disrupted because of histone
H4 depletion. This finding indicates that suboptimal TFIIIC binding to
A-block-mutated SCR1 results in a reduced ability to
counteract the assembly of repressive chromatin structures. Once again,
this effect specifically pertains to the Adown mutant. In fact,
regardless of the particular yeast strain or growth conditions,
shortened SCR1 RNAs transcribed from either 5' -32 or
TATAdown mutant minigenes accumulated at exactly the same level as WT
SCR1 minigene transcripts (data not shown).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of nucleosome disruption on in
vivo transcription of WT and A-block-mutated
SCR1. Total RNA (5 µg) extracted before
(lanes 1, 2, 5, and 6) or
after (lanes 3, 4, 7, and
8) glucose shift of the MHY308 (lanes 1-4) or
UKY403 (lanes 5-8) strains transformed with 3'-shortened
variants of either WT SCR1 (lanes 1,
3, 5, and 7) or the Adown mutant
(lanes 2, 4, 6, and 8) was
gel-fractionated and probed with a radiolabeled SCR1
antisense oligonucleotide. The migration positions of endogenous,
full-length SCR1 transcripts (scRNA) and of
plasmid-derived shortened transcripts (scRNA-mini) are
indicated on the right.
|
|
Transcription Elongation and Reinitiation on SCR1--
The typical
products of 7SL RNA genes (~300 nt) are unusually long with respect
to the ~100-nt-long RNAs commonly encoded by class III genes
(e.g. tRNAs and the 5 S rRNA). This is even more so for the
S. cerevisiae 7SL RNA gene, whose 522-nt transcript is the
longest known RNA synthesized by Pol III. The Pol III system has fairly
unique transcription reinitiation properties, being able to complete an
entire transcription cycle in vitro in time intervals as
short as 20 s and to carry out multiple rounds of transcription on
the same gene without polymerase dissociation (41, 42). These peculiar
recycling properties may in principle be a direct consequence of the
small size of class III transcriptional units that, by keeping the
transcribing Pol III in close proximity to the promoter, may augment
its probability of reinitiating on the same gene (43). We thus set out
to analyze, by single round transcription experiments, the kinetics of
reinitiation on the SCR1 gene, a 5 times longer elongation
track as compared, for example, with a typical tRNA gene. Classical
single round transcription analysis (1) relies on the formation, upon
NTP omission, of stalled ternary complexes (composed of template DNA,
transcriptional proteins, and nascent RNA) that are resistant to
heparin concentrations completely inhibiting reinitiation. The
nucleotide sequence of SCR1 is such that a stalled ternary
complex incorporating a 4-nt-long RNA can be generated at best by the
omission of UTP. On the basis of previous studies, showing slippage of
transcripts shorter than 5 nt (44), we expected that an initiated
complex containing a nascent RNA shorter than 5 nt might not be
sufficiently stable to resist heparin treatment. To solve this problem,
we introduced a C to T substitution at position +4 of SCR1.
In the absence of CTP, this mutant template (SCR1-C4T),
whose in vitro transcription efficiency was identical to
that of WT SCR1 (not shown), yielded stalled ternary
complexes bearing a 12-nt RNA and supposedly standing heparin
concentrations (~100 µg/ml) that completely inhibit reinitiation (1). The latter assumption was verified with the pulse-chase experiment
reported in Fig. 7A, in which
the 12-mer was synthesized in the presence of ATP, GTP, and
[ -32P]UTP at a high specific radioactivity, followed
by the resumption of transcription through the addition of CTP and an
800-fold molar excess of unlabeled UTP, either alone (lane
1) or with heparin (100 µg/ml) (lane 2). Under these
conditions, because of isotopic dilution, only full-length transcripts
synthesized during the first transcription cycle will incorporate
enough radioactivity so to contribute significantly to the observed
signals. Accordingly, the transcription signal in lane 1 is
a measure of the total number of unperturbed elongation-competent
ternary complexes, while the signal in lane 2 corresponds to
the fraction of such complexes that have resisted heparin perturbation.
In the experiment shown and in two additional independent experiments,
the intensities of these two signals were found to be nearly identical
(± 8%), thus proving the almost complete heparin resistance of
stalled SCR1 elongation complexes. Similar results were
obtained when ternary complexes were challenged with heparin for up to
2 min prior to NTP addition and resumption of transcription elongation (data not shown). Having established that heparin does not affect the
stability of stalled elongation complexes formed on the
SCR1-C4T template, we conducted the transcription
reinitiation analysis reported in Fig. 7B. To this end,
stalled elongation complexes were first formed on SCR1-C4T
in the absence of CTP, and then CTP was added, either alone (lane
1) or in combination with varying concentrations of heparin
(lanes 2-7), and transcription was allowed to proceed for 5 min. A heparin concentration of 25 µg/ml was found to be sufficient
to block reinitiation, whereas elongation from initiated complexes was
unaffected even by a 24-fold higher heparin concentration. In the
absence of heparin, about eight transcription cycles took place on the
SCR1-C4T gene in 5 min, corresponding to a cycle duration
time of ~40 s. The experiment reported in Fig. 7C was next
carried out to evaluate the duration time of a single elongation step
on SCR1. Stalled elongation complexes were assembled as in
the experiment reported in Fig. 7A, and then elongation was
resumed (and reinitiation was blocked) by the addition of CTP
and heparin (100 µg/ml). Aliquots of this reaction mixture were
sampled and stopped at times ranging from 5 to 60 s. As apparent from the data in Fig. 7C, no more than 20-30 s was required
to complete elongation. Since the transcribed region of SCR1
is 522 bp long, an elongation rate of ~20 nt/s can be inferred from
these data. Such a value is in good agreement with previous
measurements of yeast Pol III elongation rate on a tRNA gene (45). As
implied by these results, Pol III termination and reinitiation on
SCR1 take altogether no more than 20 s. Since the
recruitment of free Pol III by preinitiation complexes is a relatively
slow process requiring a few minutes (41), it can be concluded that
facilitated reinitiation does indeed take place on the SCR1
gene.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 7.
Transcription elongation and reinitiation on
SCR1. A, heparin stability of ternary
complexes assembled on SCR1-C4T. Ternary complexes carrying
the transcript encoded by the first 12 bp of SCR1-C4T
(32P-labeled at its four U residues) were formed by
incubation with an NTP mixture lacking CTP and then fully elongated by
the addition of CTP in the presence of an 800-fold molar excess of
unlabeled UTP with (lane 2) or without (lane 1)
heparin (100 µg/ml). B, single round transcription
analysis of reinitiation. Stalled, 12-mer RNA-containing ternary
complexes were first formed on the SCR1-C4T template, and
elongation was then resumed by the addition of CTP together with
increasing concentrations of heparin as indicated above each lane;
multiple rounds of transcription were allowed to proceed for 5 min in
the heparin-lacking reaction mixture loaded in lane 1. C, time course of transcription elongation. Elongation by
stalled ternary complexes (formed as in B) was resumed by
the addition of CTP, together with heparin (100 µg/ml) to abolish
reinitiation. At the times indicated above each
lane, aliquots of the reaction mixture were transferred to
tubes chilled in dry ice to stop the reaction. A reaction mixture
aliquot sampled before the addition of CTP was loaded in lane
1. In all panels, the migration position of the
full-length SCR1 transcript (scRNA) is indicated
on the right.
|
|
 |
DISCUSSION |
Despite its unusual length and promoter architecture,
SCR1, the gene coding for the 7SL RNA of S. cerevisiae, is transcribed by RNA polymerase III through the same
intragenic control elements (A- and B-blocks), transcriptional
components, and basic mechanisms operating in the case of classical
tRNA genes. If compared with the predominantly extragenic promoter
organization of the 7SL genes from other eukaryotes, this finding
further attests to the remarkable plasticity in promoter organization
of class III genes other than the tDNAs and the 5 S rDNAs (16). This
probably reflects the different exploitation for transcriptional
purposes of intragenic control elements, whose origin as determinants
of tRNA structure largely predates their utilization as TFIIIC binding
sites. Following the separation of eukaryotic lineages, the adaptation
to or elimination of the constraints imposed by such a dual role has
produced at least three different results. At one extreme, there is the
full coadaptation of structural and transcriptional roles as observed in present day tRNA and 5 S rRNA genes. At the other extreme, there is
the evolution of structurally unconstrained upstream control elements
that tend to confer a complete TFIIIC independence to higher eukaryotic
class III genes such as those coding for the human 7SK and U6 RNAs (5).
The third, somewhat intermediate situation relies on the maintenance of
tRNA gene-like control elements and, concomitantly, of TFIIIC function.
This is the predominant case in S. cerevisiae, where TFIIIC
function as a transcription complex assembly factor has been preserved
for all of the known class III genes. In yeast, the use of
TFIIIC-binding blocks has been reconciled with new and variable RNA
structural features either by modeling intragenic A- and B-blocks on
the structure-function requirements of the new RNA or by dislocating
one or both of these elements extragenically. The latter is the case of
the yeast RPR1 and SNR6 genes, whose
transcription depends, respectively, on an upstream tRNA gene-like
leader (33) and on a downstream extragenic B-block (37, 39), whereas a
most clear and revealing example of structural-functional adaptation is
provided by the SCR1 gene characterized in this work. An
evident signature of such an adaptation is the replacement of two
consecutive thymines at the third and fourth position of the tDNA
B-block consensus with two adenine residues (see Fig. 1). Such thymine
residues are highly conserved in tRNA genes. In particular, the thymine
at the fourth position is absolutely invariant, most probably because
it is the precursor of the essential pseudouridine residue of the tRNA
T C arm. The adenines that in the B-block of SCR1 replace
these two conserved thymine residues probably favor RNA folding and/or
function (see Ref. 46 and Fig. 1B) without being detrimental
to TFIIIC binding (47).
Important peculiarities of SCR1 promoter
organization emerge from our analysis. The first is the stronger
A-block requirement in vivo as compared with what is
observed under in vitro conditions. Such a discrepancy does
not result from an increased in vivo instability of the
A-block-altered 7SL RNA. In fact, the double CC GG substitution at
positions +19 and +20 of the A-block minimally alters the predicted secondary structure of the resulting 7SL RNA (46), and, more importantly, wild type and A-block-mutated SCR1 transcripts
displayed identical sensitivities to nuclease digestion and prolonged
incubation with yeast crude nuclear extracts (data not shown). An
explanation for the observed discrepancy between in vitro
and in vivo transcription was provided by comparative DNA
binding and transcription competition assays as well as by in
vivo nucleosome disruption experiments, carried out with different
SCR1 templates. As revealed by the results of gel
retardation and footprinting analyses, the Adown mutation considerably
reduces the affinity of SCR1 for TFIIIC and specifically
impairs the interaction of the A-block with the upstream portion of
TFIIIC. This weakened binding does not result in a proportionally
reduced in vitro transcription efficiency for at least three
possible reasons. The first of them rests upon the peculiar assembly
properties of TFIIIB, which once recruited onto the 5'-flanking region
of class III genes through interaction with TFIIIC remains tightly
bound to template DNA for multiple rounds of transcription. Thus, a
defective interaction between TFIIIC and the A-block can result in only
a moderate transcriptional impairment, provided that such interaction
is stable enough to allow the formation of long lived (kinetically
trapped (48)) TFIIIB-DNA complexes. Accordingly, a mutation in
BRF1, the gene coding for the TFIIIC-interacting
component of yeast TFIIIB, was previously selected as an extragenic
suppressor of an A-block-inactivating mutation (49), thus implying that
a defective TFIIIC-DNA interaction may still direct TFIIIB assembly as
long as a TFIIIC-anchoring site is maintained on the B-block. A second
reason for the more dramatic effect of the Adown mutation in
vivo is the existence in the nucleus of many potentially competing
class III templates. In fact, when in vitro transcription
was carried out in the presence of increasing amounts of a competitor
tDNA, transcription of the Adown mutant was much more severely reduced
than that of the wild type SCR1 gene. Finally, as revealed
by in vivo nucleosome depletion experiments, TFIIIC, when
suboptimally bound to the Adown SCR1 mutant, displayed a
dramatically reduced capacity to counteract repressive chromatin
assembly. A similar observation has been reported previously for mutant
variants of SNR6, the yeast gene coding for the U6 snRNA
(30). In this case, the TFIIIC recruiting ability of the Adown mutant
was totally compromised, and the very low transcription of the mutant
SNR6 gene upon nucleosome loss was attributed to TATA
box-mediated, TFIIIC-independent transcription. The case of
SCR1 is different, because despite the loss of
A-block-mediated TFIIIC contacts in the Adown mutant (Fig.
4B), TFIIIC is still able to recruit TFIIIB on this
template, albeit less efficiently. The SCR1 A-block can thus
be viewed as a dual function promoter element through which TFIIIC
exerts both TFIIIB recruitment and chromatin antirepression effects.
Two putative A-blocks have also been recognized between positions +5
and +22 of the human 7SL RNA gene (11), and accordingly, TFIIIC appears
to be required for human 7SL gene transcription (50). In this case,
however, the first 46 bp of the transcribed region (including the
potential A-blocks) have been shown to activate transcription through a
new mechanism involving a structural motif at the 5' end of the nascent
transcript (11). A similar structural motif is not evident in the yeast
7SL RNA (46), and the A-block mutation we introduced, although severely
affecting transcription in vivo and competition ability
in vitro, is not predicted to disturb the secondary
structure of the 7SL RNA (46) (Fig. 1B). Moreover,
footprinting analyses showed that the A-block region of SCR1
is specifically contacted by TFIIIC and that such contacts are lost in
the Adown mutant. The core function of the SCR1 A-block thus
appears to be the promotion of an optimal TFIIIC-DNA interaction.
Another interesting feature revealed by the present analysis is the
ability of the Pol III transcription machinery to support multiple
cycles of facilitated reinitiation on the unusually long SCR1 gene (522 bp). Facilitated recycling was first
described in yeast as a mechanism allowing a Pol III molecule to
repeatedly transcribe the same tRNA gene without dissociating from it
(41), and it has been proposed to play important roles also in human and plant Pol III systems (2, 51, 52). The extremely short length of
tRNA genes (100 bp on average) and the high protein occupancy of the
transcribed region (an estimated 1.5 MDa for a fully assembled Pol III
machinery) probably result in a compact, higher order nucleoprotein
complex in which the transcribing Pol III always remains in close
proximity of the transcription initiation site. Such a structural
compactness may satisfy a minimal requirement for repeated Pol III
reattachment to the same transcriptional unit (43). The fact that
facilitated recycling also takes place on a much longer transcriptional
unit leads us now to exclude the possibility that this process is
functionally restricted to small sized genes. Rather, it favors the
idea that fast recycling (hyperprocessivity) is a general property of
the Pol III system, resulting from its ability to bypass, at each
cycle, slow dissociation-reassociation steps with a wide tolerance for
the distance between initiation and termination sites. Fast recycling
on SCR1 is likely to be essential for generating the high
levels of 7SL RNA required for cell growth. In S. cerevisiae, the 7SL RNA is one of the most abundant cytoplasmic
RNA species, accounting for about 0.2% of total RNA (15). Since the
RNA/DNA ratio in a rapidly growing yeast cell (100-min duplication
time) is ~50:1 (53), it can be calculated that not less than 5000 7SL
RNA molecules/cell must be synthesized. The estimated in
vivo transcriptional output of the single copy SCR1
gene is thus on the order of 50 RNA molecules/min!
 |
ACKNOWLEDGEMENTS |
We are grateful to Michel Riva, Christophe
Carles, and Emmanuel Favry for the gift of purified RNA polymerase III;
to Peter Walter and Michael Grunstein for yeast strains; to Claudio
Rivetti, Pierre Thuriaux, and Marie-Claude Marsolier for helpful
suggestions; and to Roberto Ferrari for help with artwork.
Encouragement and support from Gian Luigi Rossi are also gratefully acknowledged.
 |
FOOTNOTES |
*
This work was supported by grants from the Ministry of
Education, University, and Research (Rome, Italy; Cofin-PRIN
program).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence may be addressed. Tel.: 39-0521-905646;
Fax: 39-0521-905151; E-mail: gdieci@unipr.it.
§
To whom correspondence may be addressed. Tel.: 39-0521-905646; Fax:
39-0521-905151; E-mail: s.ottonello@unipr.it.
Published, JBC Papers in Press, December 11, 2001, DOI 10.1074/jbc.M105036200
2
R. Percudani, unpublished results.
3
L. Bottarelli and G. Dieci, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
Pol III, RNA
polymerase III;
nt, nucleotide(s);
WT, wild type;
snRNA, small nuclear
RNA.
 |
REFERENCES |
| 1.
|
Kassavetis, G. A.,
Riggs, D. L.,
Negri, R.,
Nguyen, L. H.,
and Geiduschek, E. P.
(1989)
Mol. Cell. Biol.
9,
2551-2566[Abstract/Free Full Text]
|
| 2.
|
Yukawa, Y.,
Sugita, M.,
Choisne, N.,
Small, I.,
and Sugiura, M.
(2000)
Plant J.
22,
439-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Lee, Y.,
Wong, W. M.,
Guyer, D.,
Erkine, A. M.,
and Nazar, R. N.
(1997)
J. Mol. Biol.
269,
676-683[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Ouyang, C.,
Martinez, M. J.,
Young, L. S.,
and Sprague, K. U.
(2000)
Mol. Cell. Biol.
20,
1329-1343[Abstract/Free Full Text]
|
| 5.
|
White, R. J.
(1998)
RNA Polymerase III Transcription
, 2nd Ed.
, Springer-Verlag, Berlin, Germany
|
| 6.
|
Dieci, G.,
Percudani, R.,
Giuliodori, S.,
Bottarelli, L.,
and Ottonello, S.
(2000)
J. Mol. Biol.
299,
601-613[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Ullu, E.,
and Weiner, A. M.
(1985)
Nature
318,
371-374[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Bredow, S.,
Surig, D.,
Muller, J.,
Kleinert, H.,
and Benecke, B. J.
(1990)
Nucleic Acids Res.
18,
6779-6784[Abstract/Free Full Text]
|
| 9.
|
Kleinert, H.,
Gladen, A.,
Geisler, M.,
and Benecke, B. J.
(1988)
J. Biol. Chem.
263,
11511-11515[Abstract/Free Full Text]
|
| 10.
|
Bredow, S.,
Kleinert, H.,
and Benecke, B. J.
(1990)
Gene (Amst.)
86,
217-225[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Emde, G.,
Frontzek, A.,
and Benecke, B. J.
(1997)
RNA
3,
538-549[Abstract]
|
| 12.
|
Heard, D. J.,
Filipowicz, W.,
Marques, J. P.,
Palme, K.,
and Gualberto, J. M.
(1995)
Nucleic Acids Res.
23,
1970-1976[Abstract/Free Full Text]
|
| 13.
|
Nakaar, V.,
Dare, A. O.,
Hong, D.,
Ullu, E.,
and Tschudi, C.
(1994)
Mol. Cell. Biol.
14,
6736-6742[Abstract/Free Full Text]
|
| 14.
|
Ben-Shlomo, H.,
Levitan, A.,
Beja, O.,
and Michaeli, S.
(1997)
Nucleic Acids Res.
25,
4977-4984[Abstract/Free Full Text]
|
| 15.
|
Felici, F.,
Cesareni, G.,
and Hughes, J. M.
(1989)
Mol. Cell. Biol.
9,
3260-3268[Abstract/Free Full Text]
|
| 16.
|
Willis, I. M.
(1993)
Eur. J. Biochem.
212,
1-11[Medline]
[Order article via Infotrieve]
|
| 17.
|
Rödicker, F.,
Ossenbuhl, F.,
Michels, D.,
and Benecke, B. J.
(1999)
Gene Expr.
8,
165-174[Medline]
[Order article via Infotrieve]
|
| 18.
|
Briand, J. F.,
Navarro, F.,
Gadal, O.,
and Thuriaux, P.
(2001)
Mol. Cell. Biol.
21,
189-195[Abstract/Free Full Text]
|
| 19.
|
Hann, B. C.,
and Walter, P.
(1991)
Cell
67,
131-144[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Pavesi, A.,
Conterio, F.,
Bolchi, A.,
Dieci, G.,
and Ottonello, S.
(1994)
Nucleic Acids Res.
22,
1247-1256[Abstract/Free Full Text]
|
| 21.
|
Higuchi, R.
(1990)
in
PCR Protocols: A Guide to Methods and Applications
(Innis, M. A.
, Gelfand, D. H.
, Sninsky, J. J.
, and White, T. J., eds)
, pp. 177-183, Academic Press, Inc., San Diego
|
| 22.
|
Hill, J. E.,
Myers, A. M.,
Koerner, T. J.,
and Tzagoloff, A.
(1986)
Yeast
2,
163-167[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Dieci, G.,
Bottarelli, L.,
Ballabeni, A.,
and Ottonello, S.
(2000)
Protein Expr. Purif.
18,
346-354[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Huet, J.,
Manaud, N.,
Dieci, G.,
Peyroche, G.,
Conesa, C.,
Lefebvre, O.,
Ruet, A.,
Riva, M.,
and Sentenac, A.
(1996)
Methods Enzymol.
273,
249-267[Medline]
[Order article via Infotrieve]
|
| 25.
|
Pizzi, S.,
Dieci, G.,
Frigeri, P.,
Piccoli, G.,
Stocchi, V.,
and Ottonello, S.
(1999)
J. Biol. Chem.
274,
2539-2548[Abstract/Free Full Text]
|
| 26.
|
Ito, H.,
Fukuda, Y.,
Murata, K.,
and Kimura, A.
(1983)
J. Bacteriol.
153,
163-168[Abstract/Free Full Text]
|
| 27.
|
Wise, J. A.
(1991)
Methods Enzymol.
194,
405-415[Medline]
[Order article via Infotrieve]
|
| 28.
|
Kim, U. J.,
Han, M.,
Kayne, P.,
and Grunstein, M.
(1988)
EMBO J.
7,
2211-2219[Medline]
[Order article via Infotrieve]
|
| 29.
|
Han, M.,
and Grunstein, M.
(1988)
Cell
55,
1137-1145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Marsolier, M. C.,
Tanaka, S.,
Livingstone-Zatchej, M.,
Grunstein, M.,
Thoma, F.,
and Sentenac, A.
(1995)
Genes Dev.
9,
410-422[Abstract/Free Full Text]
|
| 31.
|
Percudani, R.,
Pavesi, A.,
and Ottonello, S.
(1997)
J. Mol. Biol.
268,
322-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Gorodkin, J.,
Knudsen, B.,
Zwieb, C.,
and Samuelsson, T.
(2001)
Nucleic Acids Res.
29,
169-170[Abstract/Free Full Text]
|
| 33.
|
Lee, J. Y.,
Evans, C. F.,
and Engelke, D. R.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
6986-6990[Abstract/Free Full Text]
|
| 34.
|
Dirheimer, G.,
Keith, G.,
Dumas, P.,
and Westhof, E.
(1995)
in
tRNA: Structure, Biosynthesis, and Function
(Söll, D.
, and RajBhandary, U. L., eds)
, pp. 93-126, American Society for Microbiology, Washington, D. C.
|
| 35.
|
Rüth, J.,
Conesa, C.,
Dieci, G.,
Lefebvre, O.,
Düsterhoft, A.,
Ottonello, S.,
and Sentenac, A.
(1996)
EMBO J.
15,
1941-1949[Medline]
[Order article via Infotrieve]
|
| 36.
|
Dieci, G.,
Duimio, L.,
Coda-Zabetta, F.,
Sprague, K. U.,
and Ottonello, S.
(1993)
J. Biol. Chem.
268,
11199-11207[Abstract/Free Full Text]
|
| 37.
|
Burnol, A. F.,
Margottin, F.,
Schultz, P.,
Marsolier, M. C.,
Oudet, P.,
and Sentenac, A.
(1993)
J. Mol. Biol.
233,
644-658[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Chalker, D. L.,
and Sandmeyer, S. B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
4927-4931[Abstract/Free Full Text]
|
| 39.
|
Eschenlauer, J. B.,
Kaiser, M. W.,
Gerlach, V. L.,
and Brow, D. A.
(1993)
Mol. Cell. Biol.
13,
3015-3026[Abstract/Free Full Text]
|
| 40.
|
Camier, S.,
Gabrielsen, O.,
Baker, R.,
and Sentenac, A.
(1985)
EMBO J.
4,
491-500[Medline]
[Order article via Infotrieve]
|
| 41.
|
Dieci, G.,
and Sentenac, A.
(1996)
Cell
84,
245-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Dieci, G.,
Corradini, R.,
Sforza, S.,
Marchelli, R.,
and Ottonello, S.
(2001)
J. Biol. Chem.
276,
5720-5725[Abstract/Free Full Text]
|
| 43.
|
Geiduschek, E. P.,
and Kassavetis, G. A.
(2001)
J. Mol. Biol.
310,
1-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Dieci, G.,
Hermann-Le Denmat, S.,
Lukhtanov, E.,
Thuriaux, P.,
Werner, M.,
and Sentenac, A.
(1995)
EMBO J.
14,
3766-3776[Medline]
[Order article via Infotrieve]
|
| 45.
|
Matsuzaki, H.,
Kassavetis, G. A.,
and Geiduschek, E. P.
(1994)
J. Mol. Biol.
235,
1173-1192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Strub, K.,
Fornallaz, M.,
and Bui, N.
(1999)
RNA
5,
1333-1347[Abstract]
|
| 47.
|
Kaiser, M. W.,
and Brow, D.
(1995)
J. Biol. Chem.
270,
11398-11495[Abstract/Free Full Text]
|
| 48.
|
Cloutier, T. E.,
Librizzi, M. D.,
Mollah, A. K.,
Brenowitz, M.,
and Willis, I. M.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
9581-9586[Abstract/Free Full Text]
|
| 49.
|
Lopez-De-Leon, A.,
Librizzi, M.,
Puglia, K.,
and Willis, I. M.
(1992)
Cell
16,
211-220
|
| 50.
|
Muller, J.,
and Benecke, B. J.
(1999)
Biochem. Cell Biol.
77,
431-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Wang, Z.,
and Roeder, R. G.
(1996)
Mol. Cell. Biol.
16,
6841-6850[Abstract]
|
| 52.
|
Fan, H.,
Sakulich, A. L.,
Goodier, J. L.,
Zhang, X.,
Qin, J.,
and Maraia, R. J.
(1997)
Cell
88,
707-715[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Warner, J. R.
(1999)
Trends Biochem. Sci.
24,
437-440[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Soragni and G. A. Kassavetis
Absolute Gene Occupancies by RNA Polymerase III, TFIIIB, and TFIIIC in Saccharomyces cerevisiae
J. Biol. Chem.,
September 26, 2008;
283(39):
26568 - 26576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. French, Y. N. Osheim, D. A. Schneider, M. L. Sikes, C. F. Fernandez, L. A. Copela, V. A. Misra, M. Nomura, S. L. Wolin, and A. L. Beyer
Visual Analysis of the Yeast 5S rRNA Gene Transcriptome: Regulation and Role of La Protein
Mol. Cell. Biol.,
July 15, 2008;
28(14):
4576 - 4587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Guffanti, R. Percudani, O. Harismendy, J. Soutourina, M. Werner, M. G. Iacovella, R. Negri, and G. Dieci
Nucleosome Depletion Activates Poised RNA Polymerase III at Unconventional Transcription Sites in Saccharomyces cerevisiae
J. Biol. Chem.,
September 29, 2006;
281(39):
29155 - 29164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Guffanti, R. Ferrari, M. Preti, M. Forloni, O. Harismendy, O. Lefebvre, and G. Dieci
A Minimal Promoter for TFIIIC-dependent in Vitro Transcription of snoRNA and tRNA Genes by RNA Polymerase III
J. Biol. Chem.,
August 18, 2006;
281(33):
23945 - 23957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Marck, R. Kachouri-Lafond, I. Lafontaine, E. Westhof, B. Dujon, and H. Grosjean
The RNA polymerase III-dependent family of genes in hemiascomycetes: comparative RNomics, decoding strategies, transcription and evolutionary implications.
Nucleic Acids Res.,
January 1, 2006;
34(6):
1816 - 1835.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Braglia, R. Percudani, and G. Dieci
Sequence Context Effects on Oligo(dT) Termination Signal Recognition by Saccharomyces cerevisiae RNA Polymerase III
J. Biol. Chem.,
May 20, 2005;
280(20):
19551 - 19562.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. ZWIEB, R. W. VAN NUES, M. A. ROSENBLAD, J. D. BROWN, and T. SAMUELSSON
A nomenclature for all signal recognition particle RNAs
RNA,
January 1, 2005;
11(1):
7 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Simms, E. C. Miller, N. P. Buisson, N. Jambunathan, and D. Donze
The Saccharomyces cerevisiae TRT2 tRNAThr gene upstream of STE6 is a barrier to repression in MAT{alpha} cells and exerts a potential tRNA position effect in MATa cells
Nucleic Acids Res.,
September 30, 2004;
32(17):
5206 - 5213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kim and V. R. Iyer
Global Role of TATA Box-Binding Protein Recruitment to Promoters in Mediating Gene Expression Profiles
Mol. Cell. Biol.,
September 15, 2004;
24(18):
8104 - 8112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ferrari, C. Rivetti, J. Acker, and G. Dieci
Distinct roles of transcription factors TFIIIB and TFIIIC in RNA polymerase III transcription reinitiation
PNAS,
September 14, 2004;
101(37):
13442 - 13447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. VAN NUES and J. D. BROWN
Saccharomyces SRP RNA secondary structures: A conserved S-domain and extended Alu-domain
RNA,
January 1, 2004;
10(1):
75 - 89.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Roberts, A. J. Stewart, J. T. Huff, and B. R. Cairns
The RNA polymerase III transcriptome revealed by genome-wide localization and activity-occupancy relationships
PNAS,
December 9, 2003;
100(25):
14695 - 14700.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|